Bone Injury Articles & Analysis
17 news found
According to the National Osteoporosis Foundation (NOF), about 54 million Americans suffer from osteoporosis, presenting low bone mass, and suffering from brittle-bone related injuries, such as fractures, and broken bones. ...
KLISBio is targeting a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed. ...
ByKLISBio
Sam shares that “I am honored to have this opportunity to participate in bringing to market this exciting and rather unique bone regeneration platform technology, and to join a team that has developed this groundbreaking medical device. ...
Significant challenges in treating peripheral nerve injuries persist within the domain of surgery and regenerative medicine, having a profound impact on patients’ quality of life. ...
ByKLISBio
KLISBio is focused on developing innovative solutions that solve prominent unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug ...
ByKLISBio
“KLISBio is focused on developing innovative solutions to tackle prominent unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained ...
ByKLISBio
KLISBio is focused on developing innovative solutions that solve prominent, unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug ...
ByKLISBio
With the profound impact on patients’ quality of life, peripheral nerve injuries remain at the forefront of treatment challenges for orthopedic surgeons. ...
ByKLISBio
Engineered silk materials provide a unique combination of outstanding biological and mechanical properties for a variety of clinical indications such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed. ...
ByKLISBio
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has submitted a supplementary De Novo application to the US Food and Drug Administration (FDA) to obtain a market approval for the company’s antibiotic-releasing product CERAMENT® G. ...
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, has been awarded a group purchasing agreement for Synthetic Implantable Products with Premier. ...
Osteochondral lesions are a tear or fracture that involves damage to both the cartilage and underlying bone. Osteochondral defects often occur in joints and are most common in the articular cartilage and subchondral bone structures of the knee and ankle. Articular cartilage injuries often occur following an acute traumatic injury ...
Founded in 2014, NuShores is the licensee of UA Little Rock’s bone regeneration products, which have been developed primarily with DoD funding. ...
Mark Pelo will lead NuShores’ production of NuCress™ bone regenerative product line. Little Rock, AR – NuShores Biosciences LLC (NuShores), founded and based in Little Rock, Arkansas, announced today that Mr. ...
HCCP technology serves as the platform for MMI’s bone regeneration product, Osteo-P™ Bone Graft Substitute (BGS). ...
Current treatment usually involves taking bone from one of the patient’s other bones, and moving it to the site of the injury. ...
Aix-en-Provence, September 14th, 2015 – GRAFTYS SA, a company focused on development and commercialization of orthopedic biomaterials, is pleased to announce that it has obtained authorization from its notified body, NSAI (National Standards Authority of Ireland) for European commercialization for two of its cements (GRAFTYS® HBS and GRAFTYS® Quickset) for treatment of ...
ByGraftys